Skip to content

Über Uns
Informiert Bleiben

BRUSTKREBS

Home
Webinare
Infografiken
Expertenkommentare
Artikel
Redaktionsgremium

BRUSTKREBS

Suche für:

Home
Webinare
Infografiken
Expertenkommentare
Artikel
Redaktionsgremium

Über Uns
Informiert Bleiben

Artikel - Brustkrebs

Eine speziell zusammengestellte Liste von Artikeln mit Peer-Review, in denen die neuesten Fortschritte bei der Diagnose und Behandlung von Patientinnen mit Brustkrebs im Frühstadium oder metastasiertem Brustkrebs behandelt werden.

Klinisches Potenzial von CDK4/6-Inhibitoren bei Brustkrebs
Dr. Rachel Würstlein

CDK4/6 inhibitors in the treatment of metastatic breast cancer: Focus on toxicity and safety

Overall Survival with Ribociclib plus Letrozole in Advanced Breast Cancer

Differences in metabolic transport and resistance mechanisms of Abemaciclib, Palbociclib, and Ribociclib

Cyclin-Dependent Kinase 4/6 Inhibitors for Treatment of Hormone Receptor–Positive, ERBB2-Negative Breast Cancer

Ribociclib and endocrine therapy as adjuvant treatment in patients with HR+/HER2- early breast cancer: Primary results from the phase III NATALEE trial

Significantly longer time to deterioration of quality of life due to CANKADO PRO-React eHealth support in HR+ HER2− metastatic breast cancer patients receiving palbociclib and endocrine therapy: primary outcome analysis of the multicenter randomized AGO-B WSG PreCycle trial

Dalpiciclib plus letrozole or anastrozole versus placebo plus letrozole or anastrozole as first-line treatment in patients with hormone receptor-positive, HER2-negative advanced breast cancer (DAWNA-2): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial

CDK4/6 inhibitor resistance in estrogen receptor positive breast cancer, a 2023 perspective

Abemaciclib plus endocrine therapy for hormone receptor-positive, HER2-negative, node-positive, high-risk early breast cancer (monarchE): results from a preplanned interim analysis of a randomised, open-label, phase 3 trial

Health-related quality of life in breast cancer patients treated with CDK4/6 inhibitors: a systematic review

Emerging systemic therapy options beyond CDK4/6 inhibitors for hormone receptor-positive HER2-negative advanced breast cancer

CDK4/6 inhibitor resistance mechanisms and treatment strategies (Review)

A look at current and potential treatment approaches for hormone receptor-positive, HER2-negative early breast cancer

Targeting CDK4 and CDK6 in cancer

Targeting CDK4 and CDK6 in cancer

Adjuvant abemaciclib combined with endocrine therapy for high-risk early breast cancer: updated efficacy and Ki-67 analysis from the monarchE study

Mechanisms of Resistance to CDK4/6 Blockade in Advanced Hormone Receptor–positive, HER2-negative Breast Cancer and Emerging Therapeutic Opportunities

CDK4 and CDK6 kinases: From basic science to cancer therapy

Adjuvant Palbociclib for Early Breast Cancer: The PALLAS Trial Results (ABCSG-42/AFT-05/BIG-14-03)

Phase I/II Trial of Exemestane, Ribociclib, and Everolimus in Women with HR+/HER2− Advanced Breast Cancer after Progression on CDK4/6 Inhibitors (TRINITI-1)

Endocrine Treatment and Targeted Therapy for Hormone Receptor–Positive, Human Epidermal Growth Factor Receptor 2–Negative Metastatic Breast Cancer: ASCO Guideline Update

The role of CDK4/6 inhibitors in early breast cancer

Palbociclib for Residual High-Risk Invasive HR-Positive and HER2-Negative Early Breast Cancer—The Penelope-B Trial

CDK4/6 inhibition in early-stage breast cancer: how far is it from becoming standard of care?

Palbociclib with adjuvant endocrine therapy in early breast cancer (PALLAS): interim analysis of a multicentre, open-label, randomised, phase 3 study

Palbociclib with adjuvant endocrine therapy in early breast cancer (PALLAS): interim analysis of a multicentre, open-label, randomised, phase 3 study

Inhibiting CDK4/6 in Breast Cancer with Palbociclib, Ribociclib, and Abemaciclib: Similarities and Differences

Cyclin-dependent kinase 4/6 inhibitors and interstitial lung disease in the FDA adverse event reporting system: a pharmacovigilance assessment

Management of Abemaciclib‐Associated Adverse Events in Patients with Hormone Receptor‐Positive, Human Epidermal Growth Factor Receptor 2‐Negative Advanced Breast Cancer: Safety Analysis of MONARCH 2 and MONARCH 3

Abemaciclib Combined With Endocrine Therapy for the Adjuvant Treatment of HR+, HER2−, Node-Positive, High-Risk, Early Breast Cancer (monarchE)

Comparison of treatment-related adverse events of different Cyclin-dependent kinase 4/6 inhibitors in metastatic breast cancer: A network meta-analysis

Health-related quality of life in premenopausal women with hormone-receptor-positive, HER2-negative advanced breast cancer treated with ribociclib plus endocrine therapy: results from a phase III randomized clinical trial (MONALEESA-7)

Health‐Related Quality of Life in MONARCH 3: Abemaciclib plus an Aromatase Inhibitor as Initial Therapy in HR+, HER2− Advanced Breast Cancer

Intrinsic and acquired resistance to CDK4/6 inhibitors and potential overcoming strategies

Overall Survival of CDK4/6-Inhibitor–Based Treatments in Clinically Relevant Subgroups of Metastatic Breast Cancer: Systematic Review and Meta-Analysis

Mechanisms of Sensitivity and Resistance to CDK4/6 Inhibition

Hematologic adverse events following palbociclib dose reduction in patients with hormone receptor–positive/human epidermal growth factor receptor 2–negative advanced breast cancer: pooled analysis from randomized phase 2 and 3 studies

Cyclin-dependent kinase 4 and 6 inhibitors for hormone receptor-positive breast cancer: past, present, and future

Overall Survival with Ribociclib plus Fulvestrant in Advanced Breast Cancer

PTEN Loss Mediates Clinical Cross-Resistance to CDK4/6 and PI3Kα Inhibitors in Breast Cancer

The Ongoing Search for Biomarkers of CDK4/6 Inhibitor Responsiveness in Breast Cancer

CDK4/6 inhibitor treatment for patients with hormone receptor-positive, HER2-negative, advanced or metastatic breast cancer: a US Food and Drug Administration pooled analysis

Health‐Related Quality of Life in MONARCH 2: Abemaciclib plus Fulvestrant in Hormone Receptor‐Positive, HER2‐Negative Advanced Breast Cancer After Endocrine Therapy

Early breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up

Diese Bildungsressource wird von Eli Lilly unterstützt.

Eli Lilly hat keinen Einfluss auf den Inhalt oder die Auswahl des Redaktionsgremiums.

Knowledge Hub

Home
Expertenkommentare
Artikel
Redaktionsgremium

Um

Über Uns
Informiert Bleiben
Datenschutzerklärung
Nutzungsbedingungen

Copyright © 2024 John Wiley & Sons, Inc. Alle Rechte vorbehalten.

Cookie-Präferenzen

Username or Email Address

Password

Remember Me

Lost your password?

Geben Sie den Suchbegriff ein und drücken Sie die Eingabetaste

Search...

Diese Website ist für die ausschließliche Nutzung durch medizinische Fachkreise vorgesehen.
Indem Sie mit dem Aufrufen dieser Website fortfahren, bestätigen Sie, dass Sie eine medizinische Fachperson sind.

This site is only for use by healthcare professionals. By continuing to view this site you are confirming that you are a healthcare professional.